A Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients with KIT altered hematologic malignancies
ENROLLING
Trial ID:
NCT05609942 Protocol # :
23-249
Phase
I/II
Disease Sites
Other specified personal risk factors, not elsewhere classified
Mycosis Fungoides
Other Hematopoietic
Non-Hodgkin's Lymphoma
Hodgkin's Lymphoma
Multiple Myeloma
Lymphoid Leukemia
Myeloid and Monocytic Leukemia
Leukemia, other
Principal Investigator
DeAngelo, Daniel, J
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #23-249
23-249